<DOC>
	<DOCNO>NCT01303172</DOCNO>
	<brief_summary>To compare , patient advance pancreatic cancer , effect IMM-101 combination gemcitabine gemcitabine alone safety tolerability ( include QoL ) , clinical sign symptom disease , select marker tumour burden immunological status , disease outcome .</brief_summary>
	<brief_title>A Trial Comparing Gemcitabine With Without IMM-101 Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically and/or cytologically confirm inoperable ductal adenocarcinoma pancreas , include mucinous variant . This include locally advanced metastatic disease ( stage III/IV ) . Presence measurable lesion least one site previously irradiate ( bone lesion , ascites pleural effusion consider measurable ) , describe follow : WHO performance status 02 serum creatinine &lt; 140 Î¼mol/L white blood cell ( WBC ) count , include differential count within normal range life expectancy &gt; 3 month randomisation acinar cell carcinoma , neuroendocrine tumour , lymphomas squamous cell carcinoma . severe , active uncontrolled infection require systemic antibiotic , antiviral antifungal treatment . previous chemotherapy treatment pancreatic cancer . eligible resection pancreatic primary tumour either refuse operation consider medically unfit operation . clinical CT evidence central nervous system ( CNS ) metastases . previous treatment IMM101 relate mycobacterial immunotherapy . serum albumin &lt; 26 g/L . Creactive protein ( CRP ) &gt; 70 mg/L . radiotherapy 6 week prior screen . depot corticosteroid 6 week prior screen . chronic use systemic corticosteroid and/or immunosuppressant drug within 2week period prior first administration study drug female patient childbearing potential , opinion Investigator , use approve method birth control (</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>